{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:47:15Z","timestamp":1761922035609,"version":"build-2065373602"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0306_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The acquired, somatic JAK2\n                      <jats:sup>V617F<\/jats:sup>\n                      mutation is the most common molecular aberration in patients with myeloproliferative neoplasms (MPN) and also significantly involved in the regulation of T\u00a0cell immunity. PD-1, PD-L1 and CTLA-4 are key immune checkpoint regulators that are elevated in patients with solid tumors, infectious diseases and chronic inflammation. We aimed further investigating the significance of immune checkpoint expression in JAK2\n                      <jats:sup>V617F<\/jats:sup>\n                      positive\u00a0MPN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0306_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The surface expression of PD-L1, PD-1 and CTLA-4 on peripheral blood leukocytes was determined by flow cytometry in 27 patients with JAK2\n                      <jats:sup>V617F<\/jats:sup>\n                      positive MPN and in a control group of 26 healthy individuals and analyzed by immune checkpoint and leukocyte subpopulation. In addition, the concentration of soluble PD-L1 (sPD-L1) in plasma was examined by ELISA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0306_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PD-1, PD-L1 and CTLA-4 are significantly overexpressed on the surface of granulocytes in JAK2 positive patients compared to the control group. Soluble PD-L1 (sPD-L1) is elevated in the plasma of JAK2 positive patients and increases with decreased renal function. In CD8+ T-cells and CD4+ T-cells there is a significant negative correlation between PD-1 expression or sPD-L1 concentration and their corresponding cell\u00a0count.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0306_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study shows a significant increase of immune checkpoint regulators on the cellular surface as well as soluble PD-L1 in JAK2 mutated patients compared to healthy individuals. Increased activation of the JAK2\/STAT signaling pathway by JAK2\n                      <jats:sup>V617F<\/jats:sup>\n                      appears to be a mechanism of reduced immune activation in patients with MPN. Immune checkpoint inhibition might therefore represent a\u00a0potential additional therapeutic target in this disease\u00a0group.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0306","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:23:47Z","timestamp":1751466227000},"page":"2318-2329","source":"Crossref","is-referenced-by-count":0,"title":["Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2\n                    <sup>V617F<\/sup>\n                    mutated myeloproliferative disorders"],"prefix":"10.1515","volume":"63","author":[{"given":"Christoph","family":"Winkler","sequence":"first","affiliation":[{"name":"Central Institute of Clinical and Chemical Laboratory Diagnostics , University Hospital of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Anliker","sequence":"additional","affiliation":[{"name":"Central Institute of Clinical and Chemical Laboratory Diagnostics , University Hospital of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology , Medical University of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Feistritzer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology , Medical University of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"H\u00f6chsmann","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine , University of Ulm , Ulm , Germany"},{"name":"Institute of Clinical Transfusion Medicine and Immunogenetics Ulm , German Red Cross Blood Transfusion Service and University Hospital of Ulm , Ulm , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine , University of Ulm , Ulm , Germany"},{"name":"Institute of Clinical Transfusion Medicine and Immunogenetics Ulm , German Red Cross Blood Transfusion Service and University Hospital of Ulm , Ulm , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Siller","sequence":"additional","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology , University Hospital Innsbruck, Tirol Kliniken GmbH , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Griesmacher","sequence":"additional","affiliation":[{"name":"Central Institute of Clinical and Chemical Laboratory Diagnostics , University Hospital of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-6313","authenticated-orcid":false,"given":"Lorin","family":"Loacker","sequence":"additional","affiliation":[{"name":"Central Institute of Clinical and Chemical Laboratory Diagnostics , University Hospital of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025103114402248487_j_cclm-2025-0306_ref_001","doi-asserted-by":"crossref","unstructured":"Bai, J, Gao, Z, Li, X, Dong, L, Han, W, Nie, J. Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade. Oncotarget 2017;8:110693\u2013707. https:\/\/doi.org\/10.18632\/oncotarget.22690.","DOI":"10.18632\/oncotarget.22690"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_002","doi-asserted-by":"crossref","unstructured":"Alsaab, HO, Sau, S, Alzhrani, R, Tatiparti, K, Bhise, K, Kashaw, SK, et al.. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017;8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561.","DOI":"10.3389\/fphar.2017.00561"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_003","doi-asserted-by":"crossref","unstructured":"Fife, BT, Bluestone, JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166\u201382. https:\/\/doi.org\/10.1111\/j.1600-065x.2008.00662.x.","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_004","doi-asserted-by":"crossref","unstructured":"Jiang, Y, Chen, M, Nie, H, Yuan, Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccines Immunother 2019;15:1111\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1571892.","DOI":"10.1080\/21645515.2019.1571892"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_005","doi-asserted-by":"crossref","unstructured":"Nirschl, CJ, Drake, CG. Molecular pathways: Co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19:4917\u201324. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-1972.","DOI":"10.1158\/1078-0432.CCR-12-1972"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_006","doi-asserted-by":"crossref","unstructured":"Bailly, C, Thuru, X, Quesnel, B. Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases. Cancers (Basel) 2021;13:3034. https:\/\/doi.org\/10.3390\/cancers13123034.","DOI":"10.3390\/cancers13123034"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_007","doi-asserted-by":"crossref","unstructured":"Loacker, L, Egger, A, Fux, V, Bellmann-Weiler, R, Weiss, G, Griesmacher, A, et al.. Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors. Clin Chem Lab Med 2023;61:2248\u201355. https:\/\/doi.org\/10.1515\/cclm-2023-0232.","DOI":"10.1515\/cclm-2023-0232"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_008","doi-asserted-by":"crossref","unstructured":"Daver, N, Basu, S, Garcia-Manero, G, Cortes, JE, Ravandi, F, Ning, J, et al.. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). Blood 2016;128:2900. https:\/\/doi.org\/10.1182\/blood.v128.22.2900.2900.","DOI":"10.1182\/blood.V128.22.2900.2900"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_009","doi-asserted-by":"crossref","unstructured":"Williams, P, Basu, S, Garcia-Manero, G, Hourigan, CS, Oetjen, KA, Cortes, JE, et al.. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 2019;125:1470\u201381. https:\/\/doi.org\/10.1002\/cncr.31896.","DOI":"10.1002\/cncr.31896"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_010","doi-asserted-by":"crossref","unstructured":"Ibrahim, M, Murphree, C, Patel, K, Mastrodomenico, M, Saba, NS, Safah, H, et al.. Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Rep (Hoboken) 2024;7:e2054. https:\/\/doi.org\/10.1002\/cnr2.2054.","DOI":"10.1002\/cnr2.2054"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_011","doi-asserted-by":"crossref","unstructured":"Choi, DC, Messali, N, Uda, NR, Abu-Zeinah, G, Kermani, P, Yabut, MM, et al.. JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms. Leukemia 2024;38:2487\u201391. https:\/\/doi.org\/10.1038\/s41375-024-02388-3.","DOI":"10.1038\/s41375-024-02388-3"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_012","doi-asserted-by":"crossref","unstructured":"Tashkandi, H, Younes, IE. Advances in molecular understanding of polycythemia vera, essential thrombocythemia, and primary myelofibrosis: towards precision medicine. Cancers (Basel) 2024;16:1679. https:\/\/doi.org\/10.3390\/cancers16091679.","DOI":"10.3390\/cancers16091679"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_013","doi-asserted-by":"crossref","unstructured":"Nangalia, J, Grinfeld, J, Green, AR. Pathogenesis of myeloproliferative Disorders. Annu Rev Pathol 2016;11:101\u201326. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044454.","DOI":"10.1146\/annurev-pathol-012615-044454"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_014","doi-asserted-by":"crossref","unstructured":"Tefferi, A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 2016;91:50\u20138. https:\/\/doi.org\/10.1002\/ajh.24221.","DOI":"10.1002\/ajh.24221"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_015","doi-asserted-by":"crossref","unstructured":"Prestipino, A, Emhardt, AJ, Aumann, K, O\u2019Sullivan, D, Gorantla, SP, Duquesne, S, et al.. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 2018;10:eaam7729. https:\/\/doi.org\/10.1126\/scitranslmed.aam7729.","DOI":"10.1126\/scitranslmed.aam7729"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_016","doi-asserted-by":"crossref","unstructured":"Guru, SA, Sumi, MP, Mir, R, Waza, AA, Bhat, MA, Zuberi, M, et al.. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum Cell 2020;33:1099\u2013111. https:\/\/doi.org\/10.1007\/s13577-020-00370-6.","DOI":"10.1007\/s13577-020-00370-6"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_017","doi-asserted-by":"crossref","unstructured":"Van Egeren, D, Kamaz, B, Liu, S, Nguyen, M, Reilly, CR, Kalyva, M, et al.. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol 2022;107:14\u20139. https:\/\/doi.org\/10.1016\/j.exphem.2021.12.364.","DOI":"10.1016\/j.exphem.2021.12.364"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_018","doi-asserted-by":"crossref","unstructured":"Morris, R, Kershaw, NJ, Babon, JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci 2018;27:1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519.","DOI":"10.1002\/pro.3519"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_019","doi-asserted-by":"crossref","unstructured":"Milosevic, FJD, J\u00e4ger, R, Schischlik, F, Ivanov, D, Eisenwort, G, Rumi, E, et al.. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol 2022;97:390\u2013400. https:\/\/doi.org\/10.1002\/ajh.26461.","DOI":"10.1002\/ajh.26461"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_020","doi-asserted-by":"crossref","unstructured":"Fu, J, Cheng, Z, Zhang, L, Wen, X, Hao, J. Effects of ruxolitinib on immune checkpoint molecule expression in JAK2\u00a0V617F-positive. Cells Clin Lab 2024;70. https:\/\/doi.org\/10.7754\/clin.lab.2024.240340.","DOI":"10.7754\/Clin.Lab.2024.240340"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_021","doi-asserted-by":"crossref","unstructured":"Chen, P, Long, J, Zhang, J, Xie, F, Wu, W, Tian, Z, et al.. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy. Inflamm Res 2024;73:263\u201376. https:\/\/doi.org\/10.1007\/s00011-023-01833-w.","DOI":"10.1007\/s00011-023-01833-w"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_022","doi-asserted-by":"crossref","unstructured":"Lee, SH, Lin, CC, Wei, CH, Chang, KP, Yuan, CT, Tsai, CH, et al.. PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. J\u00a0Pathol Clin Res 2022;8:78\u201387. https:\/\/doi.org\/10.1002\/cjp2.240.","DOI":"10.1002\/cjp2.240"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_023","doi-asserted-by":"crossref","unstructured":"Wang, L, Wheeler, DA, Prchal, JT. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 2016;44:644\u201352. https:\/\/doi.org\/10.1016\/j.exphem.2015.11.005.","DOI":"10.1016\/j.exphem.2015.11.005"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_024","doi-asserted-by":"crossref","unstructured":"Cavazzoni, A, Digiacomo, G, Volta, F, Alfieri, R, Giovannetti, E, Gnetti, L, et al.. PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC). Lung Cancer 2024;187:107438. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107438.","DOI":"10.1016\/j.lungcan.2023.107438"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_025","doi-asserted-by":"crossref","unstructured":"Khoury, JD, Solary, E, Abla, O, Akkari, Y, Alaggio, R, Apperley, JF, et al.. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_026","doi-asserted-by":"crossref","unstructured":"Braun, LM, Zeiser, R. Immunotherapy in myeloproliferative diseases. Cells 2020;9:1559. https:\/\/doi.org\/10.3390\/cells9061559.","DOI":"10.3390\/cells9061559"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_027","doi-asserted-by":"crossref","unstructured":"Cimen Bozkus, C, Roudko, V, Finnigan, JP, Mascarenhas, J, Hoffman, R, Iancu-Rubin, C, et al.. Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov 2019;9:1192\u2013207. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-1356.","DOI":"10.1158\/2159-8290.CD-18-1356"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_028","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m, MO, Riley, CH, Skov, V, Svane, IM, Hasselbalch, HC, Andersen, MH. Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology 2018;7:e1433521. https:\/\/doi.org\/10.1080\/2162402x.2018.1433521.","DOI":"10.1080\/2162402X.2018.1433521"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_029","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m, MO, Hjorts\u00f8, MD, Ahmad, SM, Met, \u00d6, Martinenaite, E, Riley, C, et al.. The JAK2V617F mutation is a target for specific T\u00a0cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 2017;31:495\u20138. https:\/\/doi.org\/10.1038\/leu.2016.290.","DOI":"10.1038\/leu.2016.290"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_030","doi-asserted-by":"crossref","unstructured":"Yadav, R, Hakobyan, N, Wang, JC. Role of next generation immune checkpoint inhibitor (ICI) therapy in Philadelphia negative classic myeloproliferative neoplasm (MPN): review of the literature. Int J Mol Sci 2023;24:12502. https:\/\/doi.org\/10.3390\/ijms241512502.","DOI":"10.3390\/ijms241512502"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_031","doi-asserted-by":"crossref","unstructured":"Hobbs, G, Cimen Bozkus, C, Moshier, E, Dougherty, M, Bar-Natan, M, Sandy, L, et al.. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv 2021;5:5086\u201397. https:\/\/doi.org\/10.1182\/bloodadvances.2021005491.","DOI":"10.1182\/bloodadvances.2021005491"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_032","doi-asserted-by":"crossref","unstructured":"Zeidan, AM, Cavenagh, J, Voso, MT, Taussig, D, Tormo, M, Boss, I, et al.. Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and pts with higher-risk myelodysplastic syndromes (HR-MDS): results from a large, international, randomized phase 2 study. Blood 2019;134:829. https:\/\/doi.org\/10.1182\/blood-2019-122896.","DOI":"10.1182\/blood-2019-122896"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_033","doi-asserted-by":"crossref","unstructured":"Zeidan, AM, Zeidner, JF, Duffield, A, Knaus, HA, Ferguson, A, Sheldon, K, et al.. Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: a phase I trial. Blood 2015;126:1666. https:\/\/doi.org\/10.1182\/blood.v126.23.1666.1666.","DOI":"10.1182\/blood.V126.23.1666.1666"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_034","doi-asserted-by":"crossref","unstructured":"Masucci, C, Passucci, M, Scalzulli, E, Carmosino, I, Capriata, M, Costa, A, et al.. Case Report: avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination. Front Oncol 2023;13:1212638. https:\/\/doi.org\/10.3389\/fonc.2023.1212638.","DOI":"10.3389\/fonc.2023.1212638"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_035","doi-asserted-by":"crossref","unstructured":"Hara, R, Kawada, H, Kikuti, YY, Kikkawa, E, Harada, K, Aoyama, Y, et al.. A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor. Int J Hematol 2021;113:606\u201310. https:\/\/doi.org\/10.1007\/s12185-020-03046-x.","DOI":"10.1007\/s12185-020-03046-x"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_036","doi-asserted-by":"crossref","unstructured":"Choi, DC, Abu-Zeinah, G, Di Giandomenico, S, Erdos, K, Scandura, J. JAK2V617F impairs T\u00a0cell differentiation in polycythemia vera. Blood 2022;140:6746\u20137. https:\/\/doi.org\/10.1182\/blood-2022-167785.","DOI":"10.1182\/blood-2022-167785"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_037","doi-asserted-by":"crossref","unstructured":"Marty, C, Lacout, C, Droin, N, Le Cou\u00e9dic, JP, Ribrag, V, Solary, E, et al.. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013;27:2187\u201395. https:\/\/doi.org\/10.1038\/leu.2013.102.","DOI":"10.1038\/leu.2013.102"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_038","doi-asserted-by":"crossref","unstructured":"Bj\u00f8rn, ME, Hasselbalch, HC. The role of reactive oxygen species in myelofibrosis and related neoplasms. Mediat Inflamm 2015;2015:648090. https:\/\/doi.org\/10.1155\/2015\/648090.","DOI":"10.1155\/2015\/648090"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_039","unstructured":"Shah, SZ, Raza, N, Irfan, M. Frequency of raised serum lactate dehydrogenase in patients with Jak2 positive polycythaemia vera. J\u00a0Ayub Med Coll Abbottabad 2021;33:447\u201350."},{"key":"2025103114402248487_j_cclm-2025-0306_ref_040","doi-asserted-by":"crossref","unstructured":"Schischlik, F, J\u00e4ger, R, Rosebrock, F, Hug, E, Schuster, M, Holly, R, et al.. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 2019;134:199\u2013210. https:\/\/doi.org\/10.1182\/blood.2019000519.","DOI":"10.1182\/blood.2019000519"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_041","doi-asserted-by":"crossref","unstructured":"Isfort, S, von Bubnoff, N, Al-Ali, HK, Becker, H, G\u00f6tze, T, le Coutre, P, et al.. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol 2024;103:2775\u201385. https:\/\/doi.org\/10.1007\/s00277-024-05867-w.","DOI":"10.1007\/s00277-024-05867-w"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_042","doi-asserted-by":"crossref","unstructured":"Yoo, SK, Fitzgerald, CW, Cho, BA, Fitzgerald, BG, Han, C, Koh, ES, et al.. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med 2025;31:869\u201380. https:\/\/doi.org\/10.1038\/s41591-024-03398-5.","DOI":"10.1038\/s41591-024-03398-5"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_043","doi-asserted-by":"crossref","unstructured":"Fujii, K, Fukuda, K, Kawakami, M, Mitani, A, Tanaka, G, Kage, H. Lung adenocarcinoma size decrease after SARS-CoV-2 vaccination during long-term pembrolizumab treatment: a case report. Case Rep Oncol 2023;16:907\u201311. https:\/\/doi.org\/10.1159\/000533705.","DOI":"10.1159\/000533705"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_044","doi-asserted-by":"crossref","unstructured":"Eslinger, C, Uson, PLS, Nagalo, BM, Borad, MJ. Spontaneous regression of advanced hepatocellular carcinoma following COVID-19 infection and vaccination: a case report and review of literature. J\u00a0Gastrointest Oncol 2024;15:1933\u20138. https:\/\/doi.org\/10.21037\/jgo-24-59.","DOI":"10.21037\/jgo-24-59"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_045","doi-asserted-by":"crossref","unstructured":"Loacker, L, Kimpel, J, B\u00e1nki, Z, Schmidt, CQ, Griesmacher, A, Anliker, M. Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine. Clin Chem Lab Med 2023;61:e17\u20139. https:\/\/doi.org\/10.1515\/cclm-2022-0787.","DOI":"10.1515\/cclm-2022-0787"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_046","doi-asserted-by":"crossref","unstructured":"Korkama, ES, Armstrong, AE, Jarva, H, Meri, S. Spontaneous remission in paroxysmal nocturnal hemoglobinuria-return to health or transition into malignancy? Front Immunol 2018;9:1749. https:\/\/doi.org\/10.3389\/fimmu.2018.01749.","DOI":"10.3389\/fimmu.2018.01749"},{"key":"2025103114402248487_j_cclm-2025-0306_ref_047","doi-asserted-by":"crossref","unstructured":"Hillmen, P, Lewis, SM, Bessler, M, Luzzatto, L, Dacie, JV. Natural history of paroxysmal nocturnal hemoglobinuria. N\u00a0Engl J Med 1995;333:1253\u20138. https:\/\/doi.org\/10.1056\/nejm199511093331904.","DOI":"10.1056\/NEJM199511093331904"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0306\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:42:20Z","timestamp":1761921740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0306\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,26]]},"published-print":{"date-parts":[[2025,10,27]]}},"alternative-id":["10.1515\/cclm-2025-0306"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0306","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}